Organon enters partnerships with Danish upstart on non-hormonal contraception
The deal entails USD 360m in milestone payments in addition to USD 10m in an upfront payment to the Danish developer Cirqle Biomedical.
by manon skov buch, translated by daniel pedersen
US-based firm Organon and Danish upstart Cirqle Biomedical, which is focused on women’s health, have inked a partnership and exclusive licensing agreement for a new, non-hormonal contraceptive candidate, the two firms announce in a joint press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
